JP2013513377A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513377A5
JP2013513377A5 JP2012542587A JP2012542587A JP2013513377A5 JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5 JP 2012542587 A JP2012542587 A JP 2012542587A JP 2012542587 A JP2012542587 A JP 2012542587A JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5
Authority
JP
Japan
Prior art keywords
identity
functionally equivalent
component
equivalent variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542587A
Other languages
English (en)
Japanese (ja)
Other versions
JP5784626B2 (ja
JP2013513377A (ja
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed filed Critical
Priority claimed from PCT/ES2010/070818 external-priority patent/WO2011070214A2/es
Publication of JP2013513377A publication Critical patent/JP2013513377A/ja
Publication of JP2013513377A5 publication Critical patent/JP2013513377A5/ja
Application granted granted Critical
Publication of JP5784626B2 publication Critical patent/JP5784626B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542587A 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物 Expired - Fee Related JP5784626B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ESP201030813 2010-05-27
ES201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (3)

Publication Number Publication Date
JP2013513377A JP2013513377A (ja) 2013-04-22
JP2013513377A5 true JP2013513377A5 (enExample) 2014-01-30
JP5784626B2 JP5784626B2 (ja) 2015-09-24

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542587A Expired - Fee Related JP5784626B2 (ja) 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物

Country Status (11)

Country Link
US (1) US8771664B2 (enExample)
EP (1) EP2511294B1 (enExample)
JP (1) JP5784626B2 (enExample)
CN (1) CN102753574B (enExample)
AU (1) AU2010329805B2 (enExample)
BR (1) BR112012013868A8 (enExample)
CA (1) CA2783876C (enExample)
ES (1) ES2463016T3 (enExample)
MX (1) MX2012006691A (enExample)
RU (1) RU2597989C2 (enExample)
WO (1) WO2011070214A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
JP2016518361A (ja) * 2013-04-19 2016-06-23 シーチューヌ ファルマCytune Pharma 血管漏出症候群の発生を抑制するサイトカイン治療
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
LT3094351T (lt) * 2014-01-15 2022-04-11 Kadmon Corporation, Llc Imunitetą moduliuojantys agentai
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
US12577323B2 (en) 2015-06-10 2026-03-17 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
US20250281583A1 (en) * 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds

Similar Documents

Publication Publication Date Title
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2022541657A5 (enExample)
JP2013541335A5 (enExample)
JP2017532045A5 (enExample)
JP2009506762A5 (enExample)
JP2019506843A5 (enExample)
JP2020528743A5 (enExample)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2017525336A5 (enExample)
JP2011502479A5 (enExample)
JP2014523238A5 (enExample)
JP2014510519A5 (enExample)
JP2010516290A5 (enExample)
FI3642340T3 (fi) Muunneltu l-asparaginaasi
JP2014508510A5 (enExample)
JP2010506826A5 (enExample)
CN101143894A (zh) 高效抑制血管生成多肽及其物理化学修饰方法和应用
JP2013515745A5 (enExample)
JP2023553697A5 (enExample)
JP2023528204A5 (enExample)
JP2009112314A5 (enExample)
JP2018500385A5 (enExample)
JP2019530441A5 (enExample)